



NAVY AND MARINE CORPS PUBLIC HEALTH CENTER
PREVENTION AND PROTECTION START HERE



Health Analysis
Navy and Marine Corps Public Health Center
620 John Paul Jones Circle
Portsmouth, VA 23708

[Healthcare Provider]
[Address]

June 1, 2013

Dear [Healthcare Provider]:

In February of 2011, the Food and Drug Administration (FDA) required new black box labeling on fluoroquinolone medications, due to a newly identified risk for the myasthenia gravis population. An association exists between fluoroquinolone use and myasthenia gravis exacerbation.

Due to this newly identified risk, the FDA mandated labeling changes for the following fluoroquinolones:

- Avelox (moxifloxacin hydrochloride) Tablets and Avelox (moxifloxacin hydrochloride in NaCl injection) I.V.
- Cipro (ciprofloxacin hydrochloride) Tablets, Oral Suspension, IV and Cipro XR (ciprofloxacin extended-release tablets)
- Noroxin (norfloxacin) Tablets
- Levaquin (levofloxacin) Tablets, Oral Solution and Injection
- Proquin XR (ciprofloxacin) Extended-Release Tablets
- Floxin (ofloxacin) Tablets
- Factive (gemifloxacin mesylate) Tablets

In collaboration with the Navy Bureau of Medicine and respective specialty leaders, the Navy and Marine Corps Public Health Center has taken steps to notify patients diagnosed with myasthenia gravis that they may be at increased risk when prescribed fluoroquinolones in their treatment or care. These patients have received a letter of notification providing the information mentioned above and a wallet notification card for use. The patients have also been advised to contact their healthcare provider for further questions.

If you have any further questions, please email health-analysis@nmcphc.med.navy.mil. For more information regarding myasthenia gravis and fluoroquinolone warnings, please visit: <http://www.med.navy.mil/sites/nmcphc/health-analysis/Pages/notifications.aspx>

Sincerely,

P. Rockswold
CAPT, MC, USN